Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Study Overview
Status
Status
Conditions
Conditions
- Carcinoma, Renal Cell
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Hepatocellular
- Carcinoma, Pancreatic
- Mesothelioma
- AML
- Cholangiocarcinoma
- Stage IV Lung Cancer
- Carcinoma, Neuroendocrine
- Stage IV Breast Cancer
- Carcinoma, Ductal
- Malignant Ascites
- Carcinoma Prostate
- Stage III Breast Cancer
- Carcinoma of the Appendix
- Carcinoma, Small Cell Lung
- Multiple Myeloma in Relapse
- Malignant Pleural Effusion
- Carcinoma Cervix
- Stage III Lung Cancer
- Carcinoma Breast
- Carcinoma of Unknown Primary
- Carcinoma of the Oral Cavity
- Carcinoma of the Oropharynx
- Carcinoma, Thymic
- Carcinoma of Lung
- Carcinoma, Ovarian
- Carcinoma Bladder
- Carcinoma of Esophagus
- Carcinoma of the Head and Neck
- Carcinoma of the Lip
- Carcinoma of the Skin
- Carcinoma of the Anus
- Carcinoma of the Larynx
- Carcinoma of the Penis
- Carcinoma of the Paranasal Sinus
- Carcinoma of the Vulva
Study Type
Study Type
Contacts and Locations
Study Contact
Study Contact
- Name: Mark Stevens, Ph.D.
- Phone Number: 6172999784
- Email: trv002@travera.com
Study Locations
-
-
Georgia
-
Columbus, Georgia, United States, 31904
- Recruiting
- Columbus Regional Research Institute, John B. Amos Cancer Center
-
Contact:
- Shelby Zikeli
- Phone Number: 706-321-0495
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Sample collection or biopsy of tumor is clinically indicated as part of SOC
- Prior to preceding onto therapy for treatment
Exclusion Criteria:
- Unable to obtain sufficient sample
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Carcinoma-Associated Malignant Fluid
Diagnosis of any kind of carcinoma with a malignant fluid (pleural effusion or ascites) where drainage is clinically indicated as part of SOC, and a new course of treatment is upcoming.
|
|
Carcinoma Solid Tissue Specimen
Diagnosis of any kind of carcinoma where a needle biopsy or tissue resection is clinically indicated as part of SOC, and a new course of treatment is upcoming.
|
|
Multiple Myeloma
Diagnosis of relapsed multiple myeloma where bone marrow biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.
|
|
Acute myelogenous leukemia (AML)
Diagnosis of acute myelogenous leukemia where a blood draw or bone marrow biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.
|
|
Triple Negative Breast Cancer (TNBC)
Diagnosis of Stage IV Triple Negative Breast Cancer where a needle biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.
|
|
Peripheral Blood Cell Immune Competency
Diagnosis of any cancer where a blood draw is clinically indicated as part of SOC, a new course of treatment is upcoming, and checkpoint inhibitor therapy being considered for next line of treatment.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Best overall response (BOR)
Time Frame: up to 24 months
|
The best overall response to therapy over 24 months will be captured for correlation with test outcomes.
|
up to 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Mark Stevens, Ph.D., Travera Inc
- Principal Investigator: Robert Kimmerling, Ph.D., Travera Inc
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Endocrine System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Pathologic Processes
- Genital Neoplasms, Male
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Genital Diseases, Male
- Prostatic Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Intestinal Diseases
- Immune System Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Colorectal Neoplasms
- Intestinal Neoplasms
- Rectal Diseases
- Genital Diseases, Female
- Lung Diseases
- Hematologic Diseases
- Endocrine Gland Neoplasms
- Head and Neck Neoplasms
- Liver Diseases
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Liver Neoplasms
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Esophageal Diseases
- Ovarian Diseases
- Adnexal Diseases
- Genital Neoplasms, Female
- Gonadal Disorders
- Adenoma
- Neoplasms, Mesothelial
- Pleural Neoplasms
- Skin Diseases
- Breast Diseases
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Urologic Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Kidney Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Neuroendocrine Tumors
- Neoplasms, Plasma Cell
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Hemorrhagic Disorders
- Urinary Bladder Diseases
- Neoplasms, Complex and Mixed
- Vulvar Diseases
- Neoplasms, Ductal, Lobular, and Medullary
- Ovarian Neoplasms
- Anus Diseases
- Pleural Diseases
- Rectal Neoplasms
- Thymus Neoplasms
- Carcinoma, Ovarian Epithelial
- Prostatic Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Lung Neoplasms
- Esophageal Neoplasms
- Mesothelioma
- Breast Neoplasms
- Carcinoma, Renal Cell
- Carcinoma, Non-Small-Cell Lung
- Cholangiocarcinoma
- Multiple Myeloma
- Small Cell Lung Carcinoma
- Carcinoma, Neuroendocrine
- Urinary Bladder Neoplasms
- Carcinoma, Small Cell
- Vulvar Neoplasms
- Carcinoma, Ductal
- Anus Neoplasms
- Thymoma
- Pleural Effusion, Malignant
- Pleural Effusion
- Ascites
Other Study ID Numbers
Other Study ID Numbers
- TRV-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.